Dave Stack: I don’t have that number specifically off the top of my head. I can tell you that one of the things that make the GPO contracting that we talked about today on the call, was the fact that the vast majority of our growth in 2023 has come from places where we have contracted business. 340B is a significant portion of that I can’t give you a number that goes with that. But what we see is where we have individual contracts or group contracts outside of 340B we do see growth and 340B also has provided growth. I’m sorry, I can’t give you a percentage, but it’s the places that we’re seeing the product growing have some form of price protection. And that’s why continuing with 340B and adding GPOs, we think provides — continues to provide access for EXPAREL in a very difficult cost environment for — especially for our hospital customers, but really for all customers. And so I’m sorry, I can’t give you a specific number, if that’s what you’re looking for.
Unidentified Analyst: No worries. Thank you.
Operator: Thank you for your question. Our next question is from Les Sulewski from Truist Securities. Your line is open.
Unidentified Analyst: Hi. This is Jeremy on for Les. Thanks for taking my questions. Firstly, any concern for how GLP-1s will impact ortho surgeries, but an overall health care population result in fewer elective surgeries. And then also, can you just walk us through the competitive landscape, specifically with ZILRETTA and other cheaper treatment options? And what type of impact have you been seeing from those? Thanks.
Dave Stack: Thank you. Very active surgery is very modest in terms of the GLP-1s for us. So on the downside, we really don’t see bariatric surgery impacting us in any way material or otherwise. On the other hand, we do have orthopedic surgeons telling us that because of the GLP-1s that there is some thought around patients with BMIs that are not appropriate for orthopedic surgery today, could well become candidates for orthopedic surgery going forward, because of the GLP-1 opportunities. And so we think, if anything, the GLP-1s are additive to the what we call procedures of ambulation, knee surgery and hip surgery, especially if these patients — these patients generally that have a high BMI are highly motivated, so the GLP-1s could very well help in that scenario.
The issue of ZILRETTA is really non-existent. Some of their contracted numbers and some of their pricing is such that it’s almost the same as generic cocktails. So it does really enter into any of our strategies in terms of any competitive things that we see going forward. The cocktail programs that we talked about today are a material issue. And you probably would have seen from the GLP-1 — on the GLP-1 topic again, that specifically Nobel, Nordisks and Eli Lilly were very aggressive in the compounders that we’re going after their GLP-1 brands. We see essentially the same activity for compounders putting combinations of generic drugs together. Generic drugs that are scheduled free controlled substances, compounds like Ketorolac and others that have black box warnings for patient safety.
None of those things are called out in any of these combinations. In fact, none of these products have any pivotal data, zero for efficacy or safety and none of them have package inserts. So there’s really no — they’ll wait for them to have a black box, because they don’t know have a package insert. So they are all being sold elicit and illegally, and we think that we are in a very strong position. All the way Eli Lilly and Novo Nordisks can on the GLP-1s we will follow some of those same strategies going forward. So when a site goes to bupivacaine alone or bupivacaine with epinephrine, essentially that allows them to buy this, seven, eight hours of pain control. In many places, they will add Dexamethasone or another steroid trying to get 10, 12 hours of duration.
